Analytics

Drug Price Transparency Reporting: State Rules, Triggers and a Process That Holds Up

Drug price transparency reporting for pharma manufacturers: state WAC triggers, deadlines, penalties, a worked example and how to stop the fire drills.

Nov 202614 min readAnalytics

Drug price transparency reporting: the short answer

Drug price transparency reporting is the set of state filings a pharmaceutical manufacturer must make when it launches a drug above a price threshold or raises a drug's wholesale acquisition cost (WAC) past a trigger, plus, in some states, an annual report of current WAC for every product sold there. By 2024, 21 states had passed these laws according to a national analysis in the Milbank Quarterly, and Goodwin's June 2025 update counts about 23. Each state sets its own WAC floor, percentage trigger, lookback window, deadline, portal and penalty, so one price change can create a filing in four states and none in the next five.

The legal summaries are easy to find. What is hard is the data. To know whether you owe a report you need clean WAC history by NDC, the right unit (30-day supply or course of therapy), each state's lookback calculated exactly the way that state defines it, launch dates, and justification narratives that finance, market access and legal all agree with. Most manufacturers run this from spreadsheets and email, which is why state reviewers keep finding missed reports.

This guide covers what the state laws require, a worked example of one price increase tested against several states, the data you need, a step-by-step process, the three ways mid-sized manufacturers run it, the mistakes that lead to penalties, and when you do not need to buy anything. It is written for government pricing, trade, market access and compliance leads at mid-sized and emerging pharma and biotech companies. It is not legal advice: your counsel decides how each statute applies to your products.

State price transparency in numbers

21states with drug price transparency laws by 2024, across 26 laws, or 33 counting amendments (Rahim and Kesselheim, Milbank Quarterly, 2025)
$10 to $400range of WAC thresholds that make a drug reportable, with increase triggers from 10% to 50% (same Milbank analysis)
$72M+in penalties California levied on 49 manufacturers between 2019 and 2021, of which about $6.7 million had been collected by 2024 (Milbank)
68.7%share of expected price increase reports Minnesota actually received, and 61.7% of expected new drug reports (Milbank)

What do state drug price transparency laws require?

There is no federal drug price transparency filing for manufacturers that works like the state laws. The closest federal obligations, such as Medicaid and 340B pricing or Open Payments under the Sunshine Act reporting rules, serve different purposes. As IntegriChain's May 2026 overview puts it, federal reporting is tied to rebates, benchmarks and payments, while state reporting emphasises public accountability and justification of high launch prices and large increases. Vermont passed the first state law in 2016. Since then the laws have settled into four kinds of obligation:

  • Price increase reports. Triggered when a drug above a WAC floor rises by more than a set percentage over a lookback window. Some states want notice before the increase takes effect, others a report after it.
  • New drug launch reports. Triggered when a new product launches at a WAC above a threshold, often tied to the Medicare Part D specialty tier threshold. Several states also catch biosimilars priced less than 15% below their reference brand.
  • Annual WAC reports. Texas, for example, wants the WAC in effect on January 1 for every NDC sold in the state, filed by January 15, whether or not the price moved.
  • Justification and supporting data. Many states ask why the price rose or why the launch price was set where it was: research and development costs, patent and exclusivity status, marketing spend, rebates, and in New Mexico's case international prices in up to 10 countries.

Examples of how far the triggers diverge, from the Milbank table, Goodwin's 2025 update and the Texas Department of State Health Services:

  • California: WAC above $40 and an increase of more than 16% over two years, with notice to purchasers before the increase, and launches above the Medicare threshold. Penalty $1,000 per day.
  • New York: WAC above $40 for a course of therapy and an increase of more than 16% counting cumulative increases in the prior 24 months. Notice is due within 60 days of the planned effective date. Up to $5,000 per day.
  • Connecticut: since HB 6669, a 16% cumulative increase over the preceding two calendar years for drugs costing $40 or more per course of treatment.
  • Texas: WAC of $100 or more for a one-month supply and an increase of more than 15% against the lowest WAC of the last calendar year, or more than 40% against the lowest WAC of the previous three calendar years. Increase reports are due within 30 days of the effective date, and each report carries a $258 fee.
  • New Mexico: WAC of $400 or more for a 30-day supply; brand increases of 10% or more in the previous calendar year or 16% or more over two calendar years; generics 30% or more.
  • Washington: increases of 20% or more on drugs above $100, launches at $10,000 or more, and, per IntegriChain, new annual 340B reporting for manufacturers.
  • Florida and Louisiana: Florida uses 15% in 12 months or 30% over three years for drugs at $100 or more; Louisiana 50% for drugs at $100 or more.
  • Oregon: launch thresholds of $950 for a 30-day supply for drugs introduced from January 1, 2025, and $670 for earlier products.

The laws keep moving. North Dakota repealed its program in 2025, New Mexico's first deadline slipped from May 1 to June 1, 2025, and sources disagree on details such as New Jersey's triggers. Treat any summary, including this one, as a starting point and confirm each statute and regulation with counsel before you build rules on it.

A worked example: one 9.5% increase, four state filings

Take one brand product from a mid-sized manufacturer. The figures are illustrative; the triggers are the ones listed above.

  • January 2024: WAC $900 for a 30-day supply.
  • January 2025: a 7% increase to $963.
  • January 2026: a 9.5% increase to $1,054.49.

The January 2026 increase is below every single-year trigger on the list. Pricing signed it off as routine. But the two-year cumulative increase, from $900 to $1,054.49, is 17.2%, and that is what several states measure.

  • California: more than 16% over two years on a drug above $40. Triggered, and the notice to purchasers was due before the increase took effect, not after.
  • New York: more than 16% counting the prior 24 months. Triggered, with notice due within 60 days of the planned effective date.
  • Connecticut: 16% cumulative over two calendar years. Triggered, if the product falls within the state's listed drugs.
  • New Mexico: 9.5% misses the 10% single-year test, but 17.2% passes the 16% two-year test. Triggered.
  • Texas: 9.5% against the lowest 2025 WAC is below 15%, and 17.2% is below 40%. No increase report, but the product still appears in the January 15 annual WAC report.
  • Washington, Florida, Louisiana: below their 20%, 15% and 50% triggers. No report.

Three lessons sit inside this example. First, you cannot decide whether to file by looking at one price change; you need the full WAC history by NDC and each state's lookback applied exactly. Second, some obligations fall due before the increase, so the check must run when pricing proposes a change, not after it posts. Third, the definitions differ in small ways that matter: "lowest WAC in the last calendar year" in Texas, "cumulative over 24 months" in New York and "over two calendar years" in New Mexico can give different answers for an increase made in July. A rules engine that encodes each definition once, and is tested against past filings, removes most of the judgement calls from the monthly cycle.

The data behind every state price report

  • WAC history by NDC

    Every WAC with its effective date for every NDC, back at least three years, from your pricing system or compendia feed, in one table that nobody edits by hand.

    • Effective date, not entry date
    • Package and unit of measure
    • Source and approver recorded
  • Product and NDC master

    The hierarchy from NDC to package to product to brand, with launch dates, brand or generic status, biosimilar reference products and the units each state uses.

    • 30-day supply and course of therapy defined
    • Launch and market entry dates
    • Discontinued NDCs kept
  • State rules table

    One maintained table of each state's WAC floor, trigger percentages, lookback definition, notice period, deadline, portal and required fields.

    • Versioned with effective dates
    • Owner in legal or government pricing
    • Reviewed every legislative session
  • Planned price changes

    Proposed increases and launch prices from pricing committee, captured before approval so advance-notice states can be tested in time.

    • Proposed effective date
    • Approval status
    • Linked to the NDCs affected
  • Justification library

    Approved narratives and figures on research and development, exclusivity, marketing, rebates and international prices, reused across states and filings.

    • Legal and finance sign-off
    • Trade secret claims documented
    • Assumptions logged with dates
  • Filing log and evidence

    What was filed, where, when, by whom, with confirmation receipts, fees paid and any regulator correspondence.

    • Portal credentials owned by the company
    • Receipts stored per filing
    • Open questions tracked to closure

How to run drug price transparency reporting without fire drills

Inventory products and states

List every NDC sold in each state and which laws can apply: price increase, launch, annual WAC and any newer obligations such as Washington's 340B reporting. Most first inventories find NDCs or states nobody had mapped.

Build one clean WAC history

Load every WAC change with effective dates into one table keyed to the NDC master, and reconcile it to the compendia. This is the foundation; every trigger depends on it.

Encode each state's rules once

Turn each state's floor, trigger, lookback and unit definition into tested rules in a versioned table, owned by government pricing and reviewed by counsel, instead of formulas copied between spreadsheets.

Test proposed changes before approval

Run every proposed increase and launch price through the rules while it is still a proposal, so the pricing committee sees which states will need notice and by when.

Generate filings and a calendar

Produce each state's template or upload file from the same data, with a calendar of due dates, owners and fees. People review and attest; they do not retype.

Reconcile and keep evidence

Each month, compare compendia WAC changes with filed reports, the same check states such as California, Minnesota and Oregon run with Medi-Span data, and store receipts and correspondence per filing.

Managed service, software or build: three ways to run it

Managed service

Government pricing and channel data firms, along with advisory practices such as Baker Tilly, offer state price transparency reporting as a service. This suits companies with a small pricing team and a handful of products. You still own the WAC data, the justifications and the attestation, so a provider cannot fix a pricing history that lives in five spreadsheets.

Compliance software

Some government pricing and contracting platforms include state transparency modules with rule libraries and filing templates. They work well when your pricing data already lives in that platform. They work less well when WAC history, product master and justifications sit elsewhere and must be loaded by hand. Vendors rarely publish prices, so compare quotes on number of NDCs, states covered and whether rule updates are included.

Build on your data stack

If you already run a commercial data warehouse with a clean NDC master, state price reporting is one more subject area: WAC history, a rules table, a trigger check and generated outputs on a schedule. The same data then feeds gross-to-net, 340B and Medicare negotiation work. It needs an owner every year, not a one-off project.

Common mistakes, and when not to buy anything

Enforcement is real and growing. California fined 49 manufacturers more than $72 million between 2019 and 2021, much of it later reduced on appeal or settled. Goodwin reports that Oregon issued $75,000 in civil penalties in 2024 and that Texas sent 33 notice of violation letters in 2024, with $5,700 in fines across 19 manufacturers. Penalties reach up to $25,000 per violation in most states, and IntegriChain notes Oregon, Minnesota and Washington are stepping up enforcement. The Milbank analysis also found that California, Minnesota and Oregon use Medi-Span price data to find increases that should have been reported, so a missed filing is easy for the state to see.

The errors behind those letters are ordinary:

  • Testing only the latest increase and missing cumulative two- and three-year triggers, as in the worked example.
  • Checking after the increase posts, when California and New York expect notice before it.
  • Wrong units: a WAC per tablet compared with a threshold per 30-day supply or course of therapy.
  • Missed launches, because nobody told the pricing team a new NDC or package size went live. Milbank notes new drug reports are harder for states to police, which is not the same as optional.
  • Portal access owned by a departed employee or a consultant; Texas requires the manufacturer's own contact details, not a third-party administrator's.
  • Justifications written fresh each time, so figures given to one state contradict another.
  • Unsupported trade secret claims, which Milbank found common and which states increasingly challenge.

When not to buy software or start a project. A pre-commercial biotech has nothing to report until launch, though launch reporting starts the day the first NDC ships, so plan it before then. A company with two or three brands, annual January price changes and no generics can often manage with a controlled workbook, a rules table reviewed by counsel and a calendar, as long as WAC history is complete. Revisit that when you add products, take mid-year increases, launch a biosimilar or sell in more states. The case for automation is strongest with many NDCs, several price changes a year, or when the same WAC history is already needed for gross-to-net and government pricing work.

Deadlines that catch manufacturers out

Before the increase: New York notice within 60 days of the planned effective date; California notice to purchasers ahead of the increase
Within 10 days, then 20 days: New Jersey's initial notification and detailed report, both counted from the market introduction or effective WAC date (IntegriChain)
Within 30 days after: Texas price increase reports, $258 per report
Within 30 days of market entry: Washington new covered drug reports, the subject of recent enforcement (Goodwin)
January 15 every year: Texas annual WAC report for every NDC sold in the state
Annually by May 1: New Mexico submissions, through a portal that opened for 2026 on February 18, 2026 (New Mexico Office of Superintendent of Insurance)

Where Greenwolf fits

Greenwolf builds the data layer underneath drug price transparency reporting. We do not give legal advice and we do not file on your behalf. We bring WAC history, the NDC master, launch dates and planned price changes into one place in your own warehouse, encode each state's triggers in a versioned rules table your counsel signs off, flag which proposed changes need notice in which states, and generate filing-ready outputs with a calendar and an exception queue. The same data feeds a pharma compliance dashboard so your government pricing lead can see every open obligation by state, product and due date.

If your product data is the weak point, start with the NDC product hierarchy. Companies building a pharma commercial data warehouse can add state price reporting as one more subject area alongside 340B rebate data and MFP effectuation. The wider picture of our pharma work is on the specialty pharmacy analytics hub. Our founder came up through pharma commercial operations consulting at ZS, so this work starts from how pricing, trade and compliance teams actually record a price change.

Questions about drug price transparency reporting

How many states have drug price transparency laws?
A 2025 Milbank Quarterly analysis by Rahim and Kesselheim counted 21 states with laws passed by 2024, and Goodwin's June 2025 update counts about 23. The number changes each session: North Dakota repealed its program in 2025 while other states added obligations, so check the current list with counsel.
What triggers a state price increase report?
A drug above the state's WAC floor rising by more than its percentage trigger within its lookback window. Floors range from $10 to $400 and triggers from 10% to 50% a year, and several states also test cumulative increases over two or three years, so a modest annual increase can still trigger a report.
Do any states require notice before a price increase?
Yes. New York requires notice within 60 days of the planned effective date for qualifying increases, and California requires notice to purchasers ahead of an increase. That is why trigger checks should run when pricing proposes a change, not after it takes effect.
What are the penalties for missing a state drug price report?
They vary by state: $1,000 per day in California and Texas, up to $5,000 per day in New York, and up to $25,000 per violation in most states according to Goodwin. California fined 49 manufacturers more than $72 million between 2019 and 2021, and Texas issued 33 notice of violation letters in 2024.
Is drug price transparency reporting the same as Sunshine Act reporting?
No. Sunshine Act reporting is the federal Open Payments filing of payments to clinicians and teaching hospitals. State drug price transparency reporting covers launch prices, WAC increases and price justifications. Both depend on clean master data, so many companies run them on the same data platform.
Do generic and biosimilar manufacturers have to report?
Often yes, under different triggers. New Mexico uses 30% for generics against 10% for brands, Virginia and New Jersey set separate generic rules, and several states catch biosimilars launched at less than 15% below the reference brand's WAC.
Can we outsource state price transparency reporting?
Yes. Specialist firms prepare and submit filings, and that suits small portfolios. You remain responsible for the accuracy of the WAC data and justifications, and you should keep portal access and filing evidence in the company's name.

Want every state price trigger checked before the increase, not after?

Tell us where your WAC history, product master and price approvals live today and we will map them in a short digital audit, then show what an automated state price reporting pipeline would look like for your portfolio.

Contact us

Reviewed by Team Greenwolf Tech Labs ยท

Part of our Pharma Commercial and Patient Analytics hub. Start with our specialty pharmacy analytics.

Talk to us

Is this a problem you are living with?

If any of the above sounds like your week, tell us which part. We will come back with what it would take to fix it.

  • A reply from a consultant, not a sales sequence
  • Usually within one working day
  • No obligation, and nothing to sit through

We reply from [email protected], usually within one working day. We do not add you to a mailing list.